FDA rejects Kala's dry eye drug; Troubled Insys finds a buyer (of some assets) in Hikma
→ Kala Pharmaceuticals, one of the plethora of biotechs that trace their roots to the prolific lab at MIT led by Bob Langer, on Thursday disclosed that its experimental drug for short-term dry eye relief did not pass muster with the FDA. Last year, the company posted mixed data from two studies — STRIDE 1 and STRIDE 2. Kala $KALA is now banking on the ongoing STRIDE 3 study to reverse its fortunes. It expects STRIDE 3 to read out by the end of the year, and to resubmit its marketing application the first half of 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
